<p>根据 Signal Advisors Wealth LLC 最近向 SEC 提交的文件，该公司在 2023 年第三季度减少了对安进（Amgen Inc.，NASDAQ:AMGN - 免费报告）的持股，降幅为 51.2%。在该季度出售了 3,226 股后，该机构投资者目前持有 3,074 股该医疗研究公司的股票。截止最近一个季度末，Signal Advisors Wealth LLC 在安进的持股价值为 867,000 美元。</p>
<ul>
<li>3 家医疗巨头刚刚提高了股息——看看谁支付得最多</li>
</ul>
<p>其他一些对冲基金也增加或减少了对 AMGN 的持股。Fairvoy Private Wealth LLC 在第二季度将其在安进的股份增加了 1.1%。Fairvoy Private Wealth LLC 目前持有 3,171 股该医疗研究公司的股票，价值为 885,000 美元，此前在上个季度购买了额外的 35 股。Nicholson Wealth Management Group LLC 在第二季度将其在安进的股份提高了 0.6%。Nicholson Wealth Management Group LLC 目前持有 5,918 股该医疗研究公司的股票，价值为 1,652,000 美元，此前在上个季度增加了 35 股。Crumly &amp; Associates Inc.在第二季度将其在安进的持股增加了 3.2%。Crumly &amp; Associates Inc.目前持有 1,146 股该医疗研究公司的股票，价值为 320,000 美元，此前在上个季度增加了 36 股。Maryland Capital Advisors Inc.在第二季度将其在安进的持股增加了 5.2%。Maryland Capital Advisors Inc.目前持有 732 股该医疗研究公司的股票，价值为 204,000 美元，此前在上个季度增加了 36 股。最后，Lion Street Advisors LLC 在第二季度将其在安进的股份增加了 1.3%。Lion Street Advisors LLC 目前持有 2,773 股该医疗研究公司的股票，价值为 774,000 美元，此前在上个季度增加了 36 股。机构投资者和对冲基金持有该公司 76.50% 的股票。</p>
<h2>分析师评级上调与下调</h2>
<p>AMGN 已成为多份研究分析师报告的主题。Erste Group Bank 在 12 月 5 日的研究报告中将安进的评级从 “持有” 上调至 “买入”。Scotiabank 在 11 月 13 日的研究报告中开始对安进进行覆盖。他们对该股票给予了 “行业表现优于大盘” 的评级，并设定了 385.00 美元的目标价。花旗集团在 9 月 24 日的研究报告中将安进的目标价从 310.00 美元上调至 315.00 美元，并给予该公司 “中性” 评级。DZ Bank 在 11 月 10 日的研究报告中将安进的目标价从 335.00 美元上调至 364.00 美元。最后，Truist Financial 在 11 月 24 日的报告中开始对安进的股票进行覆盖。他们给予了 “持有” 评级，并设定了 318.00 美元的目标价。一位研究分析师对该股票给予了强烈买入评级，十位给予了买入评级，十位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，安进目前的平均评级为 “适度买入”，平均目标价为 332.85 美元。</p>
<ul>
<li>5 家医疗公司值得关注，因为行业轮动正在全面展开</li>
</ul>
<p><strong>查看我们对 AMGN 的最新分析</strong></p>
<h2>安进价格表现</h2>
<p>安进股票在周五开盘价为 327.38 美元。该公司的 50 日移动平均线为 319.32 美元，200 日移动平均线为 300.20 美元。该公司的市值为 1,762.9 亿美元，市盈率为 25.30，市盈增长比率为 2.96，贝塔值为 0.45。安进的 12 个月低点为 257.05 美元，12 个月高点为 346.38 美元。该公司的流动比率为 1.28，速动比率为 0.99，债务股本比率为 5.45。</p>
<ul>
<li>安进股票：在盈利超预期后，新的历史高点即将到来</li>
</ul>
<p>安进（NASDAQ:AMGN - 获取免费报告）最近在 11 月 4 日发布了季度财报。该医疗研究公司报告每股收益（EPS）为 5.64 美元，超出分析师一致预期的 5.01 美元，超出幅度为 0.63 美元。安进的股本回报率为 162.59%，净利润率为 19.47%。该公司在本季度的收入为 95.6 亿美元，而一致预期为 89.8 亿美元。去年同期，该公司每股收益为 5.58 美元。与去年同期相比，该公司的收入增长了 12.4%。安进已将其 2025 财年的指引设定为每股收益 20.600-21.400 美元。作为一个整体，卖方分析师预测安进将在当前财年发布每股收益 20.62 美元。</p>
<h2>安进增加股息</h2>
<p>该公司最近宣布了一项季度股息，将于 3 月 6 日（星期五）支付。2 月 13 日（星期五）的股东将获得每股 2.52 美元的股息。这比安进之前的季度股息 2.38 美元有所增加。除息日期为 2 月 13 日（星期五）。这代表着年化股息为 10.08 美元，股息收益率为 3.1%。安进的股息支付比率为 73.57%。</p>
<h2>安进的内部交易</h2>
<p>在相关消息中，执行副总裁穆尔多·戈登于 11 月 12 日星期三出售了 6,879 股公司的股票。股票以平均价格 336.83 美元出售，总价值为 2,317,053.57 美元。出售后，这位执行副总裁直接持有 41,923 股公司的股票，价值为 14,120,924.09 美元。这笔交易代表了他们持股比例的 14.10% 的减少。该出售在向美国证券交易委员会（SEC）提交的文件中披露，相关文件可通过 SEC 网站获取。此外，高级副总裁南希·A·格里吉尔于 11 月 20 日星期四出售了 3,139 股公司的股票。股票以平均价格 337.26 美元出售，总交易额为 1,058,659.14 美元。交易完成后，这位高级副总裁直接持有 7,225 股公司的股票，价值约为 2,436,703.50 美元。这代表了他们持股比例的 30.29% 的减少。有关此次出售的更多细节可在官方 SEC 披露中找到。在过去 90 天内，内部人士出售了价值 3,674,966 美元的 10,908 股公司股票。公司内部人士持有 0.76% 的股票。</p>
<h2>安进简介</h2>
<p>（免费报告）</p>
<p>安进公司 NASDAQ: AMGN 是一家成立于 1980 年，总部位于加利福尼亚州千橡市的全球生物技术公司。该公司专注于发现、开发、制造和提供针对严重疾病的人类治疗药物。安进的工作集中在源自细胞和分子生物学的生物药物上，强调将人类遗传学和蛋白质科学的进展转化为患者的治疗方案。</p>
<p>安进的商业产品组合历史上包括用于肿瘤学、支持性护理、肾脏病、骨骼健康和心血管疾病的生物制剂。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票超过安进</li>
<li>多元化可以平滑收益并降低投资组合风险</li>
<li>这三家银行在年末前上涨，但这种趋势会持续吗？</li>
<li>如何计算通货膨胀率</li>
<li>这三只飙升的股票刚刚获得标准普尔 500 的最终认可</li>
<li>Roth IRA 计算器：计算您的潜在收益</li>
<li>这只 ETF 在美联储降息后获得了重大助力</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在安进吗？</h2>
<p>在考虑安进之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而安进并不在名单上。</p>
<p>虽然安进目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

安进

<p>Signal Advisors Wealth LLC 在第三季度减少了对安进（Amgen Inc.）的持股，降幅为 51.2%，目前市值为 867,000 美元。其他对冲基金也调整了在安进的持股。分析师的评级各不相同，平均评级为 “适度买入”，目标价为 332.85 美元。安进的第三季度收益超出预期，每股收益为 5.64 美元，收入为 95.6 亿美元。公司增加了股息，并将 2025 财年的每股收益指导目标设定在 20.600-21.400 美元</p>

<p>Signal Advisors Wealth LLC decreased its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 51.2% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 3,074 shares of the medical research company's stock after selling 3,226 shares during the quarter. Signal Advisors Wealth LLC's holdings in Amgen were worth $867,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>根据 Signal Advisors Wealth LLC 最近向 SEC 提交的文件，该公司在 2023 年第三季度减少了对安进（Amgen Inc.，NASDAQ:AMGN - 免费报告）的持股，降幅为 51.2%。在该季度出售了 3,226 股后，该机构投资者目前持有 3,074 股该医疗研究公司的股票。截止最近一个季度末，Signal Advisors Wealth LLC 在安进的持股价值为 867,000 美元。</p>
</div><ul>
<li>3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most</li>
</ul>
<div class="lb-trans"><ul>
<li>3 家医疗巨头刚刚提高了股息——看看谁支付得最多</li>
</ul>
</div><p>A number of other hedge funds have also added to or reduced their stakes in AMGN. Fairvoy Private Wealth LLC boosted its position in shares of Amgen by 1.1% during the second quarter. Fairvoy Private Wealth LLC now owns 3,171 shares of the medical research company's stock valued at $885,000 after buying an additional 35 shares during the last quarter. Nicholson Wealth Management Group LLC lifted its stake in Amgen by 0.6% during the 2nd quarter. Nicholson Wealth Management Group LLC now owns 5,918 shares of the medical research company's stock valued at $1,652,000 after acquiring an additional 35 shares in the last quarter. Crumly &amp; Associates Inc. boosted its holdings in Amgen by 3.2% during the 2nd quarter. Crumly &amp; Associates Inc. now owns 1,146 shares of the medical research company's stock worth $320,000 after acquiring an additional 36 shares during the last quarter. Maryland Capital Advisors Inc. boosted its holdings in Amgen by 5.2% during the 2nd quarter. Maryland Capital Advisors Inc. now owns 732 shares of the medical research company's stock worth $204,000 after acquiring an additional 36 shares during the last quarter. Finally, Lion Street Advisors LLC grew its stake in shares of Amgen by 1.3% in the 2nd quarter. Lion Street Advisors LLC now owns 2,773 shares of the medical research company's stock worth $774,000 after acquiring an additional 36 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company's stock.</p>
<div class="lb-trans"><p>其他一些对冲基金也增加或减少了对 AMGN 的持股。Fairvoy Private Wealth LLC 在第二季度将其在安进的股份增加了 1.1%。Fairvoy Private Wealth LLC 目前持有 3,171 股该医疗研究公司的股票，价值为 885,000 美元，此前在上个季度购买了额外的 35 股。Nicholson Wealth Management Group LLC 在第二季度将其在安进的股份提高了 0.6%。Nicholson Wealth Management Group LLC 目前持有 5,918 股该医疗研究公司的股票，价值为 1,652,000 美元，此前在上个季度增加了 35 股。Crumly &amp; Associates Inc.在第二季度将其在安进的持股增加了 3.2%。Crumly &amp; Associates Inc.目前持有 1,146 股该医疗研究公司的股票，价值为 320,000 美元，此前在上个季度增加了 36 股。Maryland Capital Advisors Inc.在第二季度将其在安进的持股增加了 5.2%。Maryland Capital Advisors Inc.目前持有 732 股该医疗研究公司的股票，价值为 204,000 美元，此前在上个季度增加了 36 股。最后，Lion Street Advisors LLC 在第二季度将其在安进的股份增加了 1.3%。Lion Street Advisors LLC 目前持有 2,773 股该医疗研究公司的股票，价值为 774,000 美元，此前在上个季度增加了 36 股。机构投资者和对冲基金持有该公司 76.50% 的股票。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级上调与下调</h2>
</div><p>AMGN has been the subject of a number of research analyst reports. Erste Group Bank raised Amgen from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Friday, December 5th. Scotiabank assumed coverage on Amgen in a research report on Thursday, November 13th. They issued a &#34;sector outperform&#34; rating and a $385.00 price objective on the stock. Citigroup raised their target price on Amgen from $310.00 to $315.00 and gave the company a &#34;neutral&#34; rating in a research report on Wednesday, September 24th. DZ Bank lifted their target price on Amgen from $335.00 to $364.00 in a research note on Monday, November 10th. Finally, Truist Financial began coverage on shares of Amgen in a report on Monday, November 24th. They issued a &#34;hold&#34; rating and a $318.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Amgen currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $332.85.</p>
<div class="lb-trans"><p>AMGN 已成为多份研究分析师报告的主题。Erste Group Bank 在 12 月 5 日的研究报告中将安进的评级从 “持有” 上调至 “买入”。Scotiabank 在 11 月 13 日的研究报告中开始对安进进行覆盖。他们对该股票给予了 “行业表现优于大盘” 的评级，并设定了 385.00 美元的目标价。花旗集团在 9 月 24 日的研究报告中将安进的目标价从 310.00 美元上调至 315.00 美元，并给予该公司 “中性” 评级。DZ Bank 在 11 月 10 日的研究报告中将安进的目标价从 335.00 美元上调至 364.00 美元。最后，Truist Financial 在 11 月 24 日的报告中开始对安进的股票进行覆盖。他们给予了 “持有” 评级，并设定了 318.00 美元的目标价。一位研究分析师对该股票给予了强烈买入评级，十位给予了买入评级，十位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，安进目前的平均评级为 “适度买入”，平均目标价为 332.85 美元。</p>
</div><ul>
<li>5 Healthcare Names to Watch as Sector Rotation Is in Full Swing</li>
</ul>
<div class="lb-trans"><ul>
<li>5 家医疗公司值得关注，因为行业轮动正在全面展开</li>
</ul>
</div><p><strong>Check Out Our Latest Analysis on AMGN</strong></p>
<div class="lb-trans"><p><strong>查看我们对 AMGN 的最新分析</strong></p>
</div><h2>Amgen Price Performance</h2>
<div class="lb-trans"><h2>安进价格表现</h2>
</div><p>AMGN stock opened at $327.38 on Friday. The firm has a 50 day moving average of $319.32 and a 200-day moving average of $300.20. The firm has a market capitalization of $176.29 billion, a P/E ratio of 25.30, a price-to-earnings-growth ratio of 2.96 and a beta of 0.45. Amgen Inc. has a 12 month low of $257.05 and a 12 month high of $346.38. The company has a current ratio of 1.28, a quick ratio of 0.99 and a debt-to-equity ratio of 5.45.</p>
<div class="lb-trans"><p>安进股票在周五开盘价为 327.38 美元。该公司的 50 日移动平均线为 319.32 美元，200 日移动平均线为 300.20 美元。该公司的市值为 1,762.9 亿美元，市盈率为 25.30，市盈增长比率为 2.96，贝塔值为 0.45。安进的 12 个月低点为 257.05 美元，12 个月高点为 346.38 美元。该公司的流动比率为 1.28，速动比率为 0.99，债务股本比率为 5.45。</p>
</div><ul>
<li>Amgen Stock: New All-Time Highs Ahead After Earnings Beat</li>
</ul>
<div class="lb-trans"><ul>
<li>安进股票：在盈利超预期后，新的历史高点即将到来</li>
</ul>
</div><p>Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings data on Tuesday, November 4th. The medical research company reported $5.64 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.01 by $0.63. Amgen had a return on equity of 162.59% and a net margin of 19.47%.The company had revenue of $9.56 billion for the quarter, compared to the consensus estimate of $8.98 billion. During the same quarter last year, the business posted $5.58 earnings per share. The firm's revenue was up 12.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. As a group, sell-side analysts predict that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>安进（NASDAQ:AMGN - 获取免费报告）最近在 11 月 4 日发布了季度财报。该医疗研究公司报告每股收益（EPS）为 5.64 美元，超出分析师一致预期的 5.01 美元，超出幅度为 0.63 美元。安进的股本回报率为 162.59%，净利润率为 19.47%。该公司在本季度的收入为 95.6 亿美元，而一致预期为 89.8 亿美元。去年同期，该公司每股收益为 5.58 美元。与去年同期相比，该公司的收入增长了 12.4%。安进已将其 2025 财年的指引设定为每股收益 20.600-21.400 美元。作为一个整体，卖方分析师预测安进将在当前财年发布每股收益 20.62 美元。</p>
</div><h2>Amgen Increases Dividend</h2>
<div class="lb-trans"><h2>安进增加股息</h2>
</div><p>The firm also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be given a dividend of $2.52 per share. This is a boost from Amgen's previous quarterly dividend of $2.38. The ex-dividend date is Friday, February 13th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 3.1%. Amgen's dividend payout ratio is 73.57%.</p>
<div class="lb-trans"><p>该公司最近宣布了一项季度股息，将于 3 月 6 日（星期五）支付。2 月 13 日（星期五）的股东将获得每股 2.52 美元的股息。这比安进之前的季度股息 2.38 美元有所增加。除息日期为 2 月 13 日（星期五）。这代表着年化股息为 10.08 美元，股息收益率为 3.1%。安进的股息支付比率为 73.57%。</p>
</div><h2>Insider Transactions at Amgen</h2>
<div class="lb-trans"><h2>安进的内部交易</h2>
</div><p>In related news, EVP Murdo Gordon sold 6,879 shares of the firm's stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $336.83, for a total value of $2,317,053.57. Following the sale, the executive vice president directly owned 41,923 shares of the company's stock, valued at $14,120,924.09. This trade represents a 14.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Nancy A. Grygiel sold 3,139 shares of the business's stock in a transaction that occurred on Thursday, November 20th. The stock was sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the completion of the transaction, the senior vice president directly owned 7,225 shares of the company's stock, valued at approximately $2,436,703.50. This represents a 30.29% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 10,908 shares of company stock valued at $3,674,966. 0.76% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在相关消息中，执行副总裁穆尔多·戈登于 11 月 12 日星期三出售了 6,879 股公司的股票。股票以平均价格 336.83 美元出售，总价值为 2,317,053.57 美元。出售后，这位执行副总裁直接持有 41,923 股公司的股票，价值为 14,120,924.09 美元。这笔交易代表了他们持股比例的 14.10% 的减少。该出售在向美国证券交易委员会（SEC）提交的文件中披露，相关文件可通过 SEC 网站获取。此外，高级副总裁南希·A·格里吉尔于 11 月 20 日星期四出售了 3,139 股公司的股票。股票以平均价格 337.26 美元出售，总交易额为 1,058,659.14 美元。交易完成后，这位高级副总裁直接持有 7,225 股公司的股票，价值约为 2,436,703.50 美元。这代表了他们持股比例的 30.29% 的减少。有关此次出售的更多细节可在官方 SEC 披露中找到。在过去 90 天内，内部人士出售了价值 3,674,966 美元的 10,908 股公司股票。公司内部人士持有 0.76% 的股票。</p>
</div><h2>Amgen Profile</h2>
<div class="lb-trans"><h2>安进简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.</p>
<div class="lb-trans"><p>安进公司 NASDAQ: AMGN 是一家成立于 1980 年，总部位于加利福尼亚州千橡市的全球生物技术公司。该公司专注于发现、开发、制造和提供针对严重疾病的人类治疗药物。安进的工作集中在源自细胞和分子生物学的生物药物上，强调将人类遗传学和蛋白质科学的进展转化为患者的治疗方案。</p>
</div><p>Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.</p>
<div class="lb-trans"><p>安进的商业产品组合历史上包括用于肿瘤学、支持性护理、肾脏病、骨骼健康和心血管疾病的生物制剂。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Amgen</li>
<li>Diversification Can Smooth Returns And Mitigate Portfolio Risk</li>
<li>These 3 Banks Are Rallying Into Year-End, But Will It Continue?</li>
<li>How to Calculate Inflation Rate</li>
<li>3 Surging Stocks Just Got the Ultimate Stamp of Approval From the S&amp;P 500</li>
<li>Roth IRA Calculator: Calculate Your Potential Returns</li>
<li>This ETF Caught a Major Tailwind After the Fed’s Rate Cut</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过安进</li>
<li>多元化可以平滑收益并降低投资组合风险</li>
<li>这三家银行在年末前上涨，但这种趋势会持续吗？</li>
<li>如何计算通货膨胀率</li>
<li>这三只飙升的股票刚刚获得标准普尔 500 的最终认可</li>
<li>Roth IRA 计算器：计算您的潜在收益</li>
<li>这只 ETF 在美联储降息后获得了重大助力</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=AMGN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Amgen Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在安进吗？</h2>
</div><p>Before you consider Amgen, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑安进之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而安进并不在名单上。</p>
</div><p>While Amgen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然安进目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Signal Advisors Wealth LLC 持有安进公司价值 867,000 美元的股票